The maternal plasma levels of bupivacaine following epidural administration of 0.5 per cent solution with 1/200,000 adrenaline were determined in twelve patients in labour. After 10 ml (50 mg) peak concentrations occurred 15-30 min later and ranged from 0.22 ^ug/ml to 0.60 ,«g/ml. Plasma levels fell gradually with time after the peak until by 3 hours after injection they were all well below 0.2 jUg/ml. Maternal and umbilical plasma levels of bupivacaine were determined at delivery. The ratio of the foetal to maternal levels varied from 0.14 to 0.86. The highest foetal plasma level obtained in the series was 0.25 wg/ml and the highest maternal level was 0.68 /ig/ml. This value was reached after three 10-ml injections of 0.5 per cent bupivacaine with 1/200,000 adrenaline. The 1-min Apgar scores ranged from 7 to 10.
Bupivacaine is a local anaesthetic of the anilide group which has been introduced fairly recently. It is claimed that it has a longer duration of action than other local anaesthetic agents of the same general type (Watt, Ross and Atkinson, 1968a, b) . The use of this compound for obstetric analgesia has been reported by Duthie, Wyman and Lewis (1968) and Bromage (1969) . It has been employed in the labour ward of the Royal Hospital for Women since 1968. Bupivacaine has been found to be a satisfactory local anaesthetic agent for obstetric use. It has a duration of action of at least 3 hours when used in a strength of 0.5 per cent with adrenaline 1/200,000 and administered by the lumbar epidural route. No clinical evidence of systemic toxicity in either the mother or neonate has yet been observed.
The present study was undertaken to obtain information on the maternal and foetal plasma concentrations attained when bupivacaine was used by the epidural route to provide obstetric analgesia. Yoshikawa, Mima and Egawa (1968) have measured blood levels of bupivacaine following its use in various situations such as axillary nerve blocks, bilateral blocks of the lower six intercostal nerves and epidural administration. Four patients received 0.5 per cent bupivacaine with 1/200,000 adrenaline at a dose of 2 mg/kg body weight by the epidural route. Peak blood levels ranging from 0.5 to 1.7 jug/'ml occurred 10-30 min after administration. A colorimetric method of determining bupivacaine was used which depends on a complex being formed between bupivacaine and cis-aconitic anhydride. This method is not specific for bupivacaine as cisaconitic anhydride is able to form a complex with a wide variety of tertiary amines. It is interesting to note that a wide patient-to-patient variation in blood levels was reported by Yoshikawa, Mima and Egawa (1968) .
A more specific method using gas chromatography has been described by Reynolds and Beckett (1968) which allows the determination of bupivacaine in the presence of lignocaine and mepivacaine.
METHODS

Subjects.
Twelve patients in labour at full term were studied in this investigation. Ten of the patients were primiparous and two had had a previous vaginal delivery. All were in the first stage of labour when the epidural analgesia was instituted and had previously been given parenteral and inhalation analgesia for various periods. All the patients were in good health and had no significant medical condition except patient No. 7 who was extremely obese.
Anaesthetic technique.
With the patient in the left lateral position a Tuohy needle was introduced into the intervertebral space between the 3rd and 4th lumbar vertebrae. The epidural space was identified by the loss of resistance technique. An initial dose of bupivacaine hydrochloride was administered. In eleven cases this was 10 ml 0.5 per cent bupivacaine hydrochloride (50 mg) with adrenaline 1/200,000, while in the twelfth case 15 ml was used. In eight patients a Portex epidural catheter was passed into the epidural space to enable subsequent doses to be administered if required. Two patients received a further 10 ml 0.5 per cent bupivacaine hydrochloride (50 mg) with 1/200,000 adrenaline and one patient received . two further doses each of 10 ml 0.5 per cent bupivacaine hydrochloride (50 mg)with 1/200,000 adrenaline. Maternal venous blood samples were taken at various times between epidural administration of bupivacaine and delivery and in some cases after delivery. At delivery maternal venous and umbilical venous blood samples were taken. Blood samples of approximately 2.5 ml were collected and stored in heparinized tubes at 4°C until assayed. The time from collecting blood samples and assaying them for bupivacaine never exceeded 3 days and preliminary experiments showed that bupivacaine is stable in blood for this period when stored at 4°C.
Estimation of bupivacaine in plasma.
The method used is fundamentally the same as the one previously reported for lignocaine (Thomas, Climie and Mather, 1968) suitably modified to the characteristics of bupivacaine. Blood samples were centrifuged at 3000 r.p.m. for 4 min and 1 ml of plasma was collected. The plasma (1.0 ml) was transferred to a 15-ml glassstoppered centrifuge tube and internal standard solution (3 ml), ether (4 ml) and sodium hydroxide solution (1 ml, 2.5N) were added. The mixture was agitated on a Vortex Genie mixer for 30 sec and the two phases separated into discrete layers by centrifuging the mixture for 2 min at 3000 r.p.m. The ether phase was transferred to a second 15-ml glass-stoppered centrifuge tube, which contained hydrochloric acid (2 ml, 0.5N), by means of a Pasteur pipette. The mixture was agitated and separated as described above. The ether phase was discarded, the aqueous phase treated with sodium hydroxide solution (2 ml, 2.5N) and then extracted with ether (4 ml) by mixing and separating as described above. The separated ether phase was transferred to a 15-ml tube with a 50-/J elongated bubble at the base. The tube was centrifuged at 500 r.p.m. for 10 min and any water which separated was removed with a hypodermic syringe fitted with a fine needle. The ethereal solution was then concentrated to about 10 /.d by immersion of the tube in a water bath maintained at 40°C. The tube was then placed in ice to condense the ether vapour and rinse down the inside of the tube. If necessary the tube was again heated at 40°C to concentrate the ether solution to approximately 10 jul. Aliquots (2-3 /A) of the ethereal solution were injected into the gas chromatograph.
A Hewlett Packard Model 5755 research gas chromatograph equipped with dual flame ionization detectors was used. The column was i inch o.d. stainless steel, 6 feet in length and packed with 10 per cent UCW-98 on 80-100 mesh Chromosorb W, AW-HMDS. Carrier gas was nitrogen at 50 ml/min and detector gas flow rates of hydrogen and air were 40 ml/min and 550 ml/min respectively. Oven temperature was maintained isothermally at 230°C while injection port and detector were both maintained at 25O°C. Retention times of bupivacaine and internal standard under these conditions were 8.6 and 10.6 min respectively.
The internal standard solution was an aqueous solution of cyproheptadine hydrochloride 1.0 /.ig/ml. Recently distilled anaesthetic ether BP was used for all extractions. The peak height method of calculating the results was found to be the most accurate and was used throughout. A calibration curve was obtained by assaying plasma with known amounts of bupivacaine added and plotting the ratio of peak heights of bupivacaine to cyproheptadine against bupivacaine added. A straight line was obtained which passed through the origin, indicating that the detector response to bupivacaine was linear over the range examined (0.25-5.0 jug).
RESULTS
Maternal plasma levels.
The maternal levels obtained following a single epidural injection of bupivacaine hydrochloride are given in table I while the corresponding values following repeated injections are given in table II. All patients reported in table I except one (patient 9) received 10 ml 0.5 per cent bupivacaine hydrochloride (50 mg) with 1/200,000 adrenaline. Patient 9 received 15 ml (75 mg) bupivacaine hydrochloride. The peak plasma levels attained with patients 1-8 ranged from 0.22 jMg/ml to 0.60 ,ag/ml. It should be pointed out that patient 7, who only reached a peak level of 0.22 jug/ml, was extremely obese (128 kg). Patient 9 attained a peak plasma level of 0.64 jUg/ml. Patients reported in table II received repeated injections of bupivacaine hydrochloride, 0.5 per cent with 1/200,000 adrenaline but in all cases they received an initial dose of 50 mg and the second dose was given well after the initial peak plasma level had been attained. The peak plasma levels found in these patients after a 50-mg dose of bupivacaine were respectively 0.41, 0.44 and 0.49 fig/ml. With both groups of patients the interval from injection to peak plasma concentration being attained ranged from 10 to 35 min. The plasma levels fell slowly after the peak concentration for 3 hours after which time no further blood samples were taken. There was little patient-to-patient variation in the pattern of rapid rise in plasma level following injection and gradual fall in levels. The results of ten patients are collected together in graphical form in figure 1 .
It can be seen from table II that repeated doses of bupivacaine hydrochloride 0.5 per cent with 1/200,000 adrenaline caused a further rise in plasma concentration with a similar time course to the initial injection. The highest plasma concentration recorded in the whole series (0.68 jUg/ml) occurred following a third dose at 375 minutes after the first dose (patient 10). Maternal plasma levels of bupivacaine following epidural administration of 10 ml 0.5 per cent bupivacaine (50 mg) with 1/200,000 adrenaline plotted against time from injection. The plot represents data from ten patients, i.e. all patients reported in tables I and II except patients 7 and 9. Each point is the mean of the values obtained at that particular time after injection. Patient 9 received 75 mg bupivacaine and patient 7 was excessively obese and had plasma levels which were atypical. Placenta! transfer of bupivacaine. The maternal and umbilical plasma concentrations of all twelve patients included in tables I and II are given in table III together with the Apgar scores of the infants. The maternal plasma concentrations at delivery ranged from 0.12 ,ug/ml to 0.41 /ig/ml while the umbilical venous plasma levels ranged from 0.04 ,Mg/ml to 0.25 /Lig/ml. The ratios of umbilical venous plasma concentrations and maternal plasma concentrations at delivery ranged from 0.14 to 0.86. The time from initial administration of bupivacaine to delivery varied from 40 to 500 min. The 1-min Apgar scores ranged from 7 to 10, reflecting the lively condition of all the infants.
DISCUSSION
The results of this investigation indicate that diffusion of bupivacaine from the epidural space follows closely the pattern reported for lignocaine, prilocaine and mepivacaine (Braid and Scott, 1965; Lund and Cwik, 1966; Lund and Covino, 1967) . The low concentrations of bupivacaine in maternal plasma reflect the small dose required to produce analgesia when administered by the epidural route. It is rather surprising that the rise in plasma concentration of bupivacaine after epidural administration follows a time course similar to lignocaine, prilocaine and mepivacaine. Peak plasma concentrations of all four compounds occur 15-30 min after injection. This does not correlate with the increased duration of analgesia obtained with bupivacaine over the other local anaesthetic agents.
A single dose of 10 ml 0.5 per cent bupivacaine hydrochloride (50 mg) with 1/200,000 adrenaline when administered into the epidural space produces satisfactory obstetric analgesia for at least 3 hours. Inspection of tables I and II reveals that by this time maternal plasma levels have fallen to very low levels. This suggests that prolonged analgesia could be obtained with bupivacaine by repeated epidural injections at approximately 3-hour intervals without maternal plasma levels rising much above the levels obtained after a single injection. The data obtained on patients 10, 11 and 12 (table II) and in particular on patient 10 supports this view.
The placental transfer of bupivacaine follows closely the pattern reported for lignocaine (Thomas, Climie and Mather, 1968; Thomas et al., 1969; Fox and Houle, 1969) . The ratio of umbilical to maternal plasma concentrations at delivery varied from 0.14 to 0.86. As with the case of lignocaine, there is no obvious explanation for the rather wide patient-to-patient variation in placental transfer of bupivacaine. No correlation can be discerned between the ratio and maternal plasma concentration at delivery or injection to delivery interval.
There have been no reports of systemic toxic effects following the clinical use of bupivacaine. Jorfeldt et al. (1968) 
